Inventor · disambiguated record
Krishna Vaddi
Also filed as: VADDI KRISHNA
12 granted patents·12 pending applications·299 citations·filing 2004–2025
92Inventor score
Files withINCYTE CORP9PRELUDE THERAPEUTICS INC5ORSENIX HOLDINGS BV4FRIEDMAN STEVEN M2RODGERS JAMES D2
Top patents by PatentIndex Score
24 records- 0198US8946245B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsRODGERS JAMES D·Filed 2011·Granted Feb 3, 2015·70 cites·26 claims
- 0298US8933086B2Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitorsINCYTE CORP·Filed 2013·Granted Jan 13, 2015·71 cites·7 claims
- 0398US8541425B2Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitorsRODGERS JAMES D·Filed 2009·Granted Sep 24, 2013·92 cites·7 claims
- 0497US9206187B2Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinaseINCYTE CORP·Filed 2013·Granted Dec 8, 2015·55 cites·26 claims
- 0592US12364664B2Lyophilized compositions comprising arsenicSYROS PHARMACEUTICALS INC·Filed 2023·Granted Jul 22, 2025·1 cites·18 claims
- 0690US10653628B2High surface-area lyophilized compositions comprising arsenic for oral administration in patientsORSENIX HOLDINGS BV·Filed 2019·Granted May 19, 2020·4 cites·16 claims
- 0784US2024269076A1High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In PatientsSYROS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0880US10111836B2High surface-area lyophilized compositions comprising arsenic for oral administration in patientsORSENIX HOLDINGS BV·Filed 2016·Granted Oct 30, 2018·3 cites·17 claims
- 0979US10272045B2High surface-area lyophilized compositions comprising arsenic for oral administration in patientsORSENIX HOLDINGS BV·Filed 2018·Granted Apr 30, 2019·2 cites·26 claims
- 1074US2022378791A1Jak1 inhibitors for the treatment of myelodysplastic syndromesINCYTE CORP·Filed 2021·Application pending·0 cites
- 1167US2025114354A1Combination treatment regimens - smarca2 degrader with pd-1 inhibitorsPRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1267US2021069193A1Jak1 inhibitors for the treatment of myelodysplastic syndromesINCYTE CORP·Filed 2020·Application pending·0 cites
- 1367US2025114353A1Combination Treatment Regimens - SMARCA2 Degrader With GemcitabinePRELUDE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1466US2021069115A1High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In PatientsORSENIX HOLDINGS BV·Filed 2020·Application pending·0 cites
- 1562US8088737B2Compositions, methods and kits relating to Her-2 cleavageFRIEDMAN STEVEN M·Filed 2004·Granted Jan 3, 2012·1 cites·12 claims
- 1662US2015238492A1Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase InhibitorsINCYTE CORP·Filed 2015·Application pending·0 cites
- 1759US2019111058A1Jak1 inhibitors for the treatment of myelodysplastic syndromesINCYTE CORP·Filed 2018·Application pending·0 cites
- 1856US9345677B2Compositions, methods and kits relating to HER-2 cleavageFRIEDMAN STEVEN M·Filed 2011·Granted May 24, 2016·0 cites·15 claims
- 1955US7910108B2Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseasesINCYTE CORP·Filed 2007·Granted Mar 22, 2011·0 cites·12 claims
- 2050US2015246046A1Jak1 inhibitors for the treatment of myelodysplastic syndromesINCYTE CORP·Filed 2015·Application pending·0 cites
- 2149US2025281473A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2249US2022218732A1Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2344US2013137681A1HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORSINCYTE CORP·Filed 2013·Application pending·0 cites
- 2443US11220524B2Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)PRELUDE THERAPEUTICS INC·Filed 2018·Granted Jan 11, 2022·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Krishna Vaddi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →